论文部分内容阅读
目的 :探讨厄贝沙坦在治疗早期糖尿病肾病的临床疗效。方法 :使用速率散射比浊法测定尿微量蛋白 ,比较厄贝沙坦组与马来酸氨氯地平组在治疗前后尿微量蛋白变化 ,及治疗组内高血压与非高血压组尿微量蛋白的变化。结果 :与对照组相比较 ,厄贝沙坦组在治疗前后尿微量蛋白有明显降低 (P <0 0 5 ) ,高血压组在治疗后微量蛋白的下降要比非高血压组明显。结论 :厄贝沙坦有减少尿蛋白的作用 ,尤其对糖尿病合并高血压病人延缓肾功能损害的进展是有益的。尿微量蛋白的测定有利于对DN患者的早期诊断。
Objective: To investigate the clinical efficacy of irbesartan in the treatment of early diabetic nephropathy. Methods: Urinary microalbuminuria was measured by rate nephelometry. The changes of urinary microalbuminuria in irbesartan and amlodipine maleate groups before and after treatment were compared with those of urine microalbuminuria in hypertensive and nonhypertensive groups Variety. Results: Compared with the control group, the urinary microalbuminuria in irbesartan group was significantly decreased (P <0.05). The decrease of microalbuminuria in hypertensive group after treatment was more significant than that in non-hypertensive group. Conclusion: Irbesartan has the effect of reducing urinary protein, especially beneficial to delay the progression of renal dysfunction in diabetic patients with hypertension. Determination of urinary trace protein is conducive to the early diagnosis of DN patients.